Autres langues BerGenBio ASA

Actions

BGBIO

NO0010650013

Temps réel Oslo Bors Autres places de cotation 09:20:55 25/04/2024			Varia. 5j.	Varia. 1 janv.
0,165 ^NOK	0,00 %		+1,98 %	-40,65 %

20/03	Bergenbio annonce le début de la phase 2A chez les patients atteints de cancer du poumon non à petites cellules en première ligne et présentant une mutation STK11	CI
14/02	BerGenBio ASA publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission	17/04
BerGenBio - Disclosure of shareholding	17/04
BerGenBio - Disclosure of large shareholding	17/04
BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue	16/04
BerGenBio ASA, Mandatory notification of trade by primary insiders and close associates	16/04
BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates	15/04
BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue	15/04
BerGenBio ASA: Last day of trading in warrants	08/04
Mandatory notification of trade by related party to Primary Insiders	08/04
BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue	03/04
BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue	02/04
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025	02/04
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025	02/04
BerGenBio ASA, Exercise price in the last exercise period for warrants issued in connection with rights issue	28/03
BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue	27/03
Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	20/03
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation	20/03
BerGenBio to Participate in Carnegie Nordic Healthcare Seminar	04/03
BerGenBio ASA - Approval and publication of a prospectus supplement	19/02
BerGenBio's Fourth Quarter 2023 Results, Focused Strategy Gathers Momentum	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BerGenBio ASA

Actions

BGBIO

NO0010650013

Autres langues

Filtres